<u>La Renon</u>

TRINITY IN SYNC



Now Available

SITAHENZ-GM 50/1/500 50/2/500

Sitagliptin 50 mg + Glimepiride 1 mg / 2 mg + Metformin 500 mg Tablets

Also Available

SITAHENZ-GM 50/1/1000 50/2/1000

Sitagliptin 50 mg + Glimepiride 1 mg / 2 mg + Metformin 1000 mg Tablets

SITAHENZ-GM


BACKGROUND

Type 2 diabetes is caused by the body's inability to respond appropriately to the effect of insulin secreted by pancreas. Progressive β -cell failure and insulin resistance are the main nuclear defects responsible for the development and progression of hyperglycemia in individuals with T2DM. Patients with type 2 diabetes mellitus (T2DM) often require multiple therapies to achieve glycemic control. As per American Diabetes Association and the European Association for the Study of Diabetes, metformin is the first drug of choice for type 2 diabetes, and DPP-4 inhibitors are cited as one of second-line drugs. Combination therapy with a dipeptidyl peptidase-4 (DPP-4) inhibitor, metformin and sulfonylurea results in substantial and additive glucose-lowering effects in patients with T2DM.

INDICATION

Sitahenz-GM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes whose diabetes are not adequately controlled with dual therapy and require additional glycemic control.

MECHANISM OF ACTION



La Renon Healthcare Private Limited

207-208, Iscon Elegance, Circle P, Prahlad Nagar Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat, India. Phone: +9179 6616 8998, 2693-6656 | Fax: +9179 6616 8998 Email: info@larenon.com | Web.: www.larenon.com



Scan QR for more Prescribing Information

😝 l am:	
© Call me on:	
Mail me at:	